JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 96.44 Billion KRW | -14.36% |
| 2022 | 112.6 Billion KRW | 28.0% |
| 2021 | 87.97 Billion KRW | 7.41% |
| 2020 | 81.9 Billion KRW | 3.96% |
| 2019 | 78.78 Billion KRW | -13.99% |
| 2018 | 91.6 Billion KRW | -5.01% |
| 2017 | 96.43 Billion KRW | -5.41% |
| 2016 | 101.94 Billion KRW | 5.04% |
| 2015 | 97.04 Billion KRW | 11.68% |
| 2014 | 86.9 Billion KRW | 2.61% |
| 2013 | 84.69 Billion KRW | -3.43% |
| 2012 | 87.7 Billion KRW | -15.56% |
| 2011 | 103.85 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 96.94 Billion KRW | -9.52% |
| 2024 Q1 | 107.14 Billion KRW | 11.1% |
| 2023 Q4 | 96.44 Billion KRW | -3.09% |
| 2023 Q3 | 99.51 Billion KRW | 2.02% |
| 2023 Q1 | 121.13 Billion KRW | 7.57% |
| 2023 FY | 96.44 Billion KRW | -14.36% |
| 2023 Q2 | 97.54 Billion KRW | -19.48% |
| 2022 Q1 | 101.55 Billion KRW | 15.43% |
| 2022 FY | 112.6 Billion KRW | 28.0% |
| 2022 Q2 | 114.24 Billion KRW | 12.5% |
| 2022 Q3 | 113.44 Billion KRW | -0.7% |
| 2022 Q4 | 112.6 Billion KRW | -0.74% |
| 2021 FY | 87.97 Billion KRW | 7.41% |
| 2021 Q1 | 85.08 Billion KRW | 3.88% |
| 2021 Q2 | 90.3 Billion KRW | 6.13% |
| 2021 Q3 | 87.18 Billion KRW | -3.45% |
| 2021 Q4 | 87.97 Billion KRW | 0.91% |
| 2020 FY | 81.9 Billion KRW | 3.96% |
| 2020 Q1 | 81.21 Billion KRW | 3.07% |
| 2020 Q2 | 112.61 Billion KRW | 38.67% |
| 2020 Q3 | 83 Billion KRW | -26.29% |
| 2020 Q4 | 81.9 Billion KRW | -1.32% |
| 2019 Q3 | 80.36 Billion KRW | -13.72% |
| 2019 Q1 | 102.86 Billion KRW | 12.29% |
| 2019 FY | 78.78 Billion KRW | -13.99% |
| 2019 Q4 | 78.78 Billion KRW | -1.96% |
| 2019 Q2 | 93.14 Billion KRW | -9.45% |
| 2018 Q3 | 93.63 Billion KRW | 7.7% |
| 2018 FY | 91.6 Billion KRW | -5.01% |
| 2018 Q4 | 91.6 Billion KRW | -2.17% |
| 2018 Q2 | 86.94 Billion KRW | -12.04% |
| 2018 Q1 | 98.84 Billion KRW | 2.5% |
| 2017 Q1 | 94.06 Billion KRW | -7.73% |
| 2017 Q2 | 89.16 Billion KRW | -5.21% |
| 2017 Q3 | 98.19 Billion KRW | 10.13% |
| 2017 Q4 | 96.43 Billion KRW | -1.8% |
| 2017 FY | 96.43 Billion KRW | -5.41% |
| 2016 FY | 101.94 Billion KRW | 5.04% |
| 2016 Q4 | 101.94 Billion KRW | 12.63% |
| 2016 Q3 | 90.51 Billion KRW | -6.4% |
| 2016 Q2 | 96.7 Billion KRW | 0.0% |
| 2015 Q4 | 97.04 Billion KRW | 0.0% |
| 2015 FY | 97.04 Billion KRW | 11.68% |
| 2014 FY | 86.9 Billion KRW | 2.61% |
| 2013 FY | 84.69 Billion KRW | -3.43% |
| 2012 FY | 87.7 Billion KRW | -15.56% |
| 2011 FY | 103.85 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -23.871% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 89.627% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 86.361% |
| HANDOK Inc. | 449.7 Billion KRW | 78.554% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -12.575% |
| Yuhan Corporation | 712.33 Billion KRW | 86.461% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 84.738% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -506.772% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 88.678% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -80.171% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 53.155% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -28.299% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 34.745% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -36.991% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -23.871% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -164.69% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 61.599% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 56.302% |
| JW Holdings Corporation | 827.51 Billion KRW | 88.345% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 77.93% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 83.564% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 74.593% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -21.616% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -37.84% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 60.287% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 70.801% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -23.871% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 80.318% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 88.76% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 74.593% |
| Yuhan Corporation | 712.33 Billion KRW | 86.461% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 79.816% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 29.587% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 81.334% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 74.593% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 37.592% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -7.2% |
| CKD Bio Corp. | 170.76 Billion KRW | 43.521% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 60.431% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 38.827% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -124.187% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -21.616% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 84.753% |
| Boryung Corporation | 373.1 Billion KRW | 74.151% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 53.677% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 53.155% |